ABSI
Absci Corp
NASDAQ · Biotechnology
$2.70
+0.17 (+6.52%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 6.18M | 6.29M | 59.64M | 58.57M | 57.07M |
| Net Income | -140,642,494 | -128,832,818 | -8,952,069 | -8,944,093 | -9,875,873 |
| EPS | — | — | — | — | — |
| Profit Margin | -2,274.1% | -2,160.4% | -15.0% | -15.3% | -17.3% |
| Rev Growth | -1.8% | -1.8% | +20.4% | +10.3% | +2.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 4.50M | 4.50M | 128.53M | 100.48M | 118.62M |
| Total Equity | 198.13M | 198.13M | 293.38M | 298.85M | 311.81M |
| D/E Ratio | 0.02 | 0.02 | 0.44 | 0.34 | 0.38 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -121,515,235 | -117,495,647 | -13,022,432 | -15,160,350 | -13,058,914 |
| Free Cash Flow | — | — | -9,238,978 | -10,726,027 | -11,756,277 |